Intracisternal Administration of NR2 Antagonists Attenuates Facial Formalin-induced Nociceptive Behavior in Rats

Aims: To examine the antinociceptive effects of N-Methyl-D-aspar-tate (NMDA) receptor NR2 subunit antagonists in a rat model of the facial formalin test. Methods: Experiments were carried out on adult male Sprague-Dawley rats weighing 220 to 280 g. Anesthetized rats were individually mounted on a stereotaxic frame and a polyethylene tube was implanted for intracisternal injection and, 72 hours later, formalin tests were performed. NMDA receptor antagonists were administered intracisternally 10 minutes prior to subcutaneous injection of 5% formalin (50 µL) into the vibrissal pad. Results: The intracisternal administration of 25, 50, or 100 µg of memantine, an antagonist that acts at the NMDA ion channel site, significantly suppressed the number of scratches in the second phase of the behavioral responses to formalin. Intracisternal admin-istration of a range of doses of 5,7-dichlorokynurenic acid, a glycine site antagonist, or DL-2-amino-5-phosphonopentanoate (AP-5), a nonselective NMDA site antagonist, produced significant antinoci-ceptive effects in the second phase. Intracisternal administration of 1, 2.5, or 5 µg of (2R,4S)-4-(3 Phosphonopropyl)-2-piperidine -carboxylic acid (PPPA), a competitive NR2A antagonist, significantly suppressed the number of scratches in the second phase, while only the highest dose of PPPA (5 µg) significantly suppressed the number of scratches in the first phase. The antinociceptive effects of intracisternal injection of (αR,βS)-α-(4Hydroxyphenyl)-β methyl-4-(phenylmethyl)-1-Piperidinepropanol maleate (Ro 25-6981), a selective NR2B antagonist, were similar to those of PPPA. Injection of memantine, AP-5, Ro 25-6981, or vehicle did not result in any motor dysfunction. A low dose of PPPA (1 μg) or 5,7-dichlorokynurenic acid (2.5 μg) did not affect motor function. However, higher doses of PPPA and 5,7-dichlorokynurenic acid produced motor dysfunction. Conclusion: The present results suggest that central NR2 subunits play an important role in orofacial nociceptive transmission. Moreover, this data also indicate that targeted inhibition of the NMDA receptor NR2 subunit is a potentially important new treatment approach for inflammatory pain origi-nating in the orofacial area.

antinociception;formalin;NMDA;NR2 receptor;orofacial pain

1. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999;51:7–61.

2. Paoletti P, Neyton J. NMDA receptor subunits: Function and pharmacology. Curr Opin Pharmacol 2007;7:39–47.

3. Childers WE Jr, Baudy RB. N-methyl-D-aspartate antagonists and neuropathic pain: The search for relief. J Med Chem 2007;50:2557–2562.

4. McBain CJ, Mayer ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994;74:723–760.

5. Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995;34:1219–1237.

6. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005;179:4–129.

7. Yamakura T, Shimoji K. Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 1999;59:279–298.

8. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: Diversity, development and disease. Curr Opin Neurobiol 2001;11:327–335.

9. Gaunitz C, Schüttler A, Gillen C, Allgaier C. Formalin-induced changes of NMDA receptor subunit expression in the spinal cord of the rat. Amino Acids 2002;23:177–182.

10. Malmberg AB, Gilbert H, McCabe RT, Basbaum AI. Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain 2003;101:109–116.

11. Bernardi M, Bertolini A, Szczawinska K, Genedani S. Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice. Eur J Pharmacol 1996;298:51–55.

12. Taniguchi K, Shinjo K, Mizutani M, et al. Antinociceptive activity of CP101, 606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol 1997;122:809–812.

13. Boyce S, Wyatt A, Webb JK, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B sub-unit in dorsal horn. Neuropharmacology 1999;38:611–623.

14. Liu XJ, Gingrich JR, Vargas-Caballero M, et al. Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nat Med 2008;14:1325–1332.

15. Lee J, Ro JY. Differential regulation of glutamate receptors in trigeminal ganglia following masseter inflammation. Neurosci Lett 2007;421:91–95.

16. Dong XD, Mann MK, Kumar U, et al. Sex-related differ-ences in NMDA-evoked rat masseter muscle afferent discharge result from estrogen-mediated modulation of peripheral NMDA receptor activity. Neuroscience 2007; 146:822–832.

17. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976;17:1031–1036.

18. Wang XM, Zhang ZJ, Bains R, Mokha SS. Effect of antisense knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain 2002;98:27–35.

19. Ahn DK, Choi HS, Yeo SP, et al. Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory tem-poromandibular joint (TMJ) nociception. Pain 2007;132: 23–32.

20. Lee MK, Choi BY, Yang GY, et al. Low doses of cannabinoids enhance the antinociceptive effects of intracisternally administered mGluRs groups II and III agonists in formalin-induced TMJ nociception in rats. Pain 2008;139: 367–375.

21. Clavelou P, Pajot J, Dallel R, Raboisson P. Application of the formalin test to the study of orofacial pain in the rat. Neurosci Lett 1989;103:349–353.

22. Gilbert SD, Clark TM, Flores CM. Antihyperalgesic activity of epibatidine in the formalin model of facial pain. Pain 2001;89:159–165.

23. Choi HS, Ju JS, Lee HJ, et al. Effects of TNF-alpha injected intracisternally on the nociceptive jaw-opening reflex and orofacial formalin test in freely moving rats. Prog Neuropsychopharmacol Biol Psychiatry 2003;27: 613–618.

24. Choi HS, Ju JS, Lee HJ, Kim BC, Park JS, Ahn DK. Effects of intracisternal injection of interleukin-6 on nociceptive jaw opening reflex and orofacial formalin test in freely moving rats. Brain Res Bull 2003;59:365–370.

25. Lee HJ, Choi HS, Jung CY, et al. Intracisternal NMDA produces analgesia in the orofacial formalin test of freely moving rats. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:497–503.

26. Peng HY, Chang HM, Chang SY, et al. Orexin-A modu-lates glutamatergic NMDA-dependent spinal reflex potentiation via inhibition of NR2B subunit. Am J Physiol Endocrinol Metab 2008;295:117–129.

27. Gabra BH, Kessler FK, Ritter JK, Dewey WL, Smith FL. Decrease in N-methyl-D-aspartic acid receptor-NR2B subunit levels by intrathecal short-hairpin RNA blocks group I metabotropic glutamate receptor-mediated hyperalgesia. J Pharmacol Exp Ther 2007;322:186–194.

28. Christoph T, Reissmüller E, Schiene K, Englberger W, Chizh BA. Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: Possible peripheral mech-anisms. Brain Red 2005;1048:218–227.

29. Berrino L, Oliva P, Massimo F, et al. Antinociceptive effect in mice of intraperitoneal Nmethyl-D-aspartate receptor antagonists in the formalin test. Eur J Pain 2003; 7:131–137.

30. Ahn DK, Lim EJ, Kim BC, et al. Compression of the trigeminal ganglion produces prolonged nociceptive behavior in rats. Eur J Pain 2009;13:568–575.

31. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: A review. Anesth Analg 2003;97:1108–1116.

32. Davies SN, Lodge D. Evidence for involvement of N-methyl-aspartate receptors in "wind-up" of class 2 neurones in the dorsal horn of the rat. Brain Res 1987;424: 402–406.

33. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987;26:1235–1238.

34. Fisher K, Coderre TJ, Hagen NA. Targeting N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000; 20:358–373.

35. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 2000;16:S73–S79.

36. Chiang CY, Park SJ, Kwan CL, Hu JW, Sessle BJ. NMDA receptor mechanisms contribute to neuroplasticity induced in caudalis nociceptive neurons by tooth pulp stimulation. J Neurophysiol 1998;80:2621–2631.

37. Luccarini P, Sessle BJ, Woda A. Superficial and deep convergent nociceptive neurons are differentially affected by

N- methyl-D-aspartate applied on the brainstem surface of the rat medullary dorsal horn. Neuroscience 2001;107: 311–316.

38. Park SJ, Chiang CY, Hu JW, Sessle BJ. Neuroplasticity induced by tooth pulp stimulation in trigeminal subnucleus oralis involves NMDA receptor mechanisms. J Neurophysiol 2001;85:1836–1846.

39. Cairns BE, Sessle BJ, Hu JW. Temporomandibular-evoked jaw muscle reflex: Role of brain stem NMDA and non-NMDA receptors. Neuroreport 2001;12:1875–1878.

40. Gielen M, Siegler Retchless B, Mony L, Johnson JW, Paoletti P. Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 2009;459: 703–707.

41. Momiyama A. Distinct synaptic and extrasynaptic NMDA receptors identified in dorsal horn neurones of the adult rat spinal cord. J Physiol 2000;523:621–628.

42. Karlsson U, Sjödin J, Angeby Möller K, Johansson S, Wikström L, Nasström J. Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn: Effects of peripheral nerve lesion and inflammation. Neuroscience 2002;112:861–868.

43. Liaw WJ, Zhu XG, Yaster M, Johns RA, Gauda EB, Tao YX. Distinct expression of synaptic NR2A and NR2B in the central nervous system and impaired morphine toler-ance and physical dependence in mice deficient in post -synaptic density-93 protein. Mol Pain 2008;4:45.

44. Ultenius C, Linderoth B, Meyerson BA, Wallin J. Spinal NMDA receptor phosphorylation correlates with the presence of neuropathic signs following peripheral nerve injury in the rat. Neurosci Lett 2006;399:85–90.

45. Petrenko AB, Yamakura T, Baba H, Sakimura K. Unaltered pain-related behavior in mice lacking NMDA receptor GluR epsilon 1 subunit. Neurosci Res 2003;46:199–204.

46. Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature 1997;386:721–724.

47. Ma QP, Hargreaves RJ. Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats. Neuroscience 2000;101:699–707.

48. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: Focus on the NR2B subtype. Trends Pharmacol Sci 2001;22:636–642.

49. Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci 2002;5:1039–1042.

50. Chizh BA, Headley PM. NMDA antagonists and neuro-pathic pain: Multiple drug targets and multiple uses. Curr Pharm Des 2005;11:2977–2994.

51. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325:529–531.

52. Cai SX. Glycine/NMDA receptor antagonists as potential CNS therapeutic agents: ACEA-1021 and related compounds. Curr Top Med Chem 2006;6:651–662.

53. Quartaroli M, Fasdelli N, Bettelini L, Maraia G, Corsi M. GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice. Eur J Pharmacol 2001;430:219–227.

54. Quartaroli M, Carignani C, Dal Forno G, et al. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A. J Pharmacol Exp Ther 1999;290:158–169.